Top Tweets for #Cancermoonshot
@HunterBiden @JDVance Hey Hunt ...you aint took me up on discussing
#21stCenturyCuresAct 2016! Passed limpduck after Trump's HUGE Victory . Supposed to be a #CancerMoonshot For Beau Biden Foundation ! Maybe they cut you OUT ! 1.8 Billion from mandated sale of
25 Million Barrels of SPR Light Sweet
💙 In memory of Asal Sayas, whose leadership, compassion, and advocacy inspired so many. We were honored to feature her Cancer Moonshot update at our 2024 Patient Empowerment Summit. Watch her segment: https://t.co/yHNt1UCFBc #InMemory #CancerMoonshot #CancerAdvocacy
GBM no longer has to be a death sentence ... your own immune system can be trained to fight back, turning deadly cancer into a treatable illness 💪 🧠
#cancer #immunology #gbm #braincancer #research #practice #cancersurvivor #curecancer #cancermoonshot #savealife #cancervaccine
A 20 year glioblastoma survivor treated with #dcvax will be speaking on Capitol Hill next week at the Parker Institute’s Congressional Briefing on Cancer Vaccines. $NWBO is officially in the same conversation as some of the most prominent cancer vaccine institutions in the world
"It says it all" 🧙🦄
"Scientist || Immigrant || Senior Fellow @HarvardChanSPH || Fmr: White House #CancerMoonshot, @CornellBME, @TEDFellow || 🇿🇦 +"
Everything Liberal has become so plastic and fake.
The cover of the Lancet. It says it all.
A qualitative analysis of #CancerMoonshot finds ARPA-H emerged as the program’s central administrative priority. Read the analysis by Michael Turtz, Director of Administration at the Charles E. Schmidt College of Medicine. https://t.co/80ky94LyJS
A qualitative analysis of #CancerMoonshot finds ARPA-H emerged as the program’s central administrative priority. Read the analysis by Michael Turtz, Director of Administration at the Charles E. Schmidt College of Medicine. https://t.co/YnXCa1vfkS @MTurtz
A qualitative analysis of #CancerMoonshot finds Advanced Research Projects Agency for Health as the top priority. The article was written by Michael Turtz, at the Charles E. Schmidt College of Medicine and a PhD candidate. Read it here: https://t.co/M783W2OgIn
@LoriMills4CA42 @POTUS @SecKennedy @DrMakaryFDA Would be great if they'd get #RadioGel @RadioGel @VivosIncUSA approved for tumors. Wouldn't need chemo and the tumor would be gone in a couple months. Trump could be the real #cancermoonshot POTUS.
Research cures cancer. Cutting federal research funding is taking hope away from Americans who have the misfortune to get sick. #CancerMoonshot #Science #NIH
Harvard researcher Joan Brugge says her work has the potential to prevent breast cancer, but she was notified last spring that her federal funding was terminated. “It was just like a gut punch. My knees buckled, and I had to sit down,” she says.
Research cures cancer. Cutting federal research funding is taking hope away from Americans who have the misfortune to get sick. #CancerMoonshot #Science #NIH
“We are truly putting the brakes on scientific innovation in this country at a time when our ostensible adversary, China, is going faster and faster and faster,” says Harvard scientist Don Ingber. “If we can’t be the leader, we’re going to be the follower.” https://t.co/6UCqfCoWbs
for my $NWBO friends.. this was shared by the CEO of Advent this morning 😊
There is a Cure for Brain Cancer & all solid tumors. It’s called the DCVax. I was administered the DCVax after being diagnosed with a Glioblastoma Multiforme Marker 4 way back in 2015. I’ve had no tumor recurrence in 10 years & 8 months.
NWBO DCVax The Future of
Personalized Immunotherapy.
@DrCatharineY Lol I would run circles around you, Cat. 🦁 and I've never been invited to TED. 😏
Scientist || Immigrant || Senior Fellow @HarvardChanSPH || Fmr: White House #CancerMoonshot, @CornellBME, @TEDFellow || 🇿🇦 + 🇺🇸
I find your credentials to be fake and ghey.
$nwbo @alphavestcap
https://t.co/ZCPqf9j0ES
Andrew Caravello, DO
@andrewcaravello
👁️ The Hidden Layer: How #AI + #IRIS + #Eden Unlock the Next Chapter for $NWBO #DCVax
#NWBO $NWBO #DCVax #IRIS #Eden #Flaskworks #AI #CancerMoonshot #PediatricCancer #CNPV #PrecisionMedicine
🪬 TLDR
President Trump’s executive order promises to harness AI to cure pediatric cancer. That promise isn’t rhetorical. It’s already unfolding:
•IRIS 🪶 — a true AI pipeline (UCLA/CHOP/Penn) that mines massive RNA datasets, applies machine learning filters, and validates tumor-specific splice-derived antigens.
•DCVax 💉 — the dendritic cell vaccine chassis that turns those antigens into immune lesson plans.
•Eden ⚙️ — Flaskworks’ automated bioreactor, patent-protected, SI 87–compliant, reproducible anywhere.
•Poly-ICLC 🚀 — a TLR3 agonist booster that ignites interferon cascades, supercharging immune memory.
•CNPV 🎟️ — FDA’s Commissioner’s National Priority Voucher, reserved for pediatric cancers, compressing approval to 30–60 days.
And it’s not a concept. UCLA is running NCT06342908 right now, treating children with deadly H3 G34–mutant gliomas using AI-curated, peptide-pulsed dendritic cells under full GMP.
1️⃣ Where AI Enters the Fight
AI’s role isn’t vague here — it’s central.
•Data ingestion: IRIS consumes petabytes of tumor RNA-seq data from TCGA, CCDI’s pediatric cancer initiative, and GTEx.
•Error detection: Machine learning models identify splicing abnormalities — skipped exons, cryptic junctions, microexons — unseen in normal tissues.
•Ranking & prediction: Neural networks and probabilistic algorithms rank which peptides will bind MHC, remain stable, and be immunogenic.
•Validation: AI outputs are cross-checked against immunopeptidomics (mass spectrometry of tumor-displayed peptides) to prove they are real targets, not computer artifacts.
Without AI, this splicing chaos looks like noise. With AI, it’s a goldmine of targets. This is the only way to turn millions of aberrations into a short, validated antigen panel fast enough to matter for a sick child.
2️⃣ Why Pediatric Cancers Are the Perfect Fit
Traditional immunotherapies often fail in pediatrics because:
•Low mutation burden ? not enough DNA mutations to create targets.
•Small patient numbers ? difficult to run large randomized trials.
•Toxicity ceiling ? children cannot tolerate the side effects of chemo, CAR-T, or systemic cytokines.
IRIS solves the first problem by unlocking splicing-derived targets, abundant in pediatric gliomas and sarcomas. DCVax solves the second by being safe, autologous, and already proven tolerable in hundreds of adults. Poly-ICLC addresses the third by providing an immune amplifier without systemic toxicity.
For children with survival measured in months, this is the architecture that finally fits.
3️⃣ From Algorithm to Immune Lesson
The IRIS ? DCVax pipeline is beautifully direct:
1. Sequence the tumor ? AI identifies splicing-derived peptides.
2. Curate & synthesize ? GMP-grade peptides produced with sterility/purity checks.
3. Load onto DCs ? dendritic cells derived from leukapheresis, matured, pulsed with IRIS peptides.
4. Infuse back ? vaccine teaches T-cells to recognize those tumor-specific errors.
5. Boost with Poly-ICLC ? expands response breadth and durability via TLR3-mediated interferon signaling.
This is what “AI cures cancer” looks like in practice — algorithms find the signals, dendritic cells deliver the lesson, boosters seal the memory.
4️⃣ Proof in Patients: UCLA’s Trial
At UCLA today (NCT06342908):
•Children and young adults with H3 G34–mutant gliomas are being treated.
•Dr. Robert Prins and Dr. Linda Liau lead — the same architects behind DCVax-L’s landmark glioblastoma trial.
•Tumors are sequenced, IRIS (or derivative pipelines) curate splicing-derived peptides.
•Vaccines are manufactured under full GMP in UCLA’s Gene & Cell Therapy Facility, using the same release standards as commercial ATMPs.
•Poly-ICLC is added as a booster.
This is the first active trial fusing AI antigen discovery with dendritic cell delivery in pediatric patients. It isn’t hype. It’s alive in children today.
The Voucher That Collapses Time
Normally, therapies for rare or pediatric cancers spend years grinding through the FDA review process. The new Commissioner’s National Priority Voucher (CNPV) program is designed to collapse that timeline.
•The FDA has announced this as a pilot program in 2025.
•In the first year, the agency plans to grant up to five vouchers total across all applicants.
•Each voucher allows the recipient therapy to be reviewed on an accelerated 30–60 day timeline, rather than the usual multi-year process.
•After the pilot, FDA has signaled that the number of vouchers may expand, but the initial run is tightly capped.
For NWBO, this matters enormously. DCVax is a platform, already validated and safe in adults. Adding IRIS peptides doesn’t create a brand-new product — it’s a spec update to the same chassis. That’s exactly the kind of refinement CNPV was built to accelerate.
If pediatric cancer programs qualify, NWBO’s submission could move in months, not years once filed under CNPV.
6️⃣ Eden: The Immune Forge
Eden isn’t just a machine. It’s the hardware kernel of the immune operating system.
•Patent-protected (EDITH, US 10,647,954 B1): covers perfusion geometry, anti-dead-zone flow, sterile transfer ports, programmed differentiation schedules.
•Closed system: eliminates contamination, standardizes DC output across sites.
•Plug-and-play: any antigen set (lysate, IRIS, or hybrid) can be dropped in without changing the licensed process.
Eden + SI 87 (UK law) means IRIS updates are controlled variations, not new licenses. The MHRA’s WHO-Listed Authority status means one UK approval can cascade into reliance markets globally.
That’s how AI findings become reproducible vaccines at scale.
7️⃣ The Human Face
Look back at Kennedy’s Oval Office photo: children at the desk, families behind them. These aren’t statistics. They are living proof of urgency.
For decades, pediatric glioma patients have been given months, not years. Radiation buys time at the cost of cognition. Chemo rarely works. CAR-T and mRNA can’t find targets.
Now AI can decode tumors for errors no child’s body has ever seen. DCVax can show those errors to the immune system. Poly-ICLC amplifies the response. And the voucher can collapse years into weeks.
This is the first time those families can look at a President’s words and know: the science is already here.
📜 Closing Thought
“AI will cure cancer” usually sounds like a politician’s flourish. But in pediatric oncology, the architecture already exists:
•AI (IRIS) finds the signals.
•DCVax delivers the immune lesson.
•Eden ensures reproducibility.
•Poly-ICLC strengthens memory.
•CNPV collapses time.
This isn’t just aspiration. It is a functioning system — alive in children right now, with regulatory rails ready to carry it worldwide.
👩⚕️ Plea to
@SecKennedy
Families fighting pediatric brain cancer don’t have years to wait. IRIS + DCVax + Eden is already in children today. Please make sure these programs are prioritized for the first CNPV vouchers. Every month matters. Every child matters.
#NWBO $NWBO #DCVax #IRIS #Eden #Flaskworks #AI #CancerMoonshot #PediatricCancer #CNPV #Immunotherapy #RareDisease #Oncology #PrecisionMedicine
👁️ The Hidden Layer: How #AI + #IRIS + #Eden Unlock the Next Chapter for $NWBO #DCVax
#NWBO $NWBO #DCVax #IRIS #Eden #Flaskworks #AI #CancerMoonshot #PediatricCancer #CNPV #PrecisionMedicine
🪬 TLDR
President Trump’s executive order promises to harness AI to cure pediatric cancer. That promise isn’t rhetorical. It’s already unfolding:
•IRIS 🪶 — a true AI pipeline (UCLA/CHOP/Penn) that mines massive RNA datasets, applies machine learning filters, and validates tumor-specific splice-derived antigens.
•DCVax 💉 — the dendritic cell vaccine chassis that turns those antigens into immune lesson plans.
•Eden ⚙️ — Flaskworks’ automated bioreactor, patent-protected, SI 87–compliant, reproducible anywhere.
•Poly-ICLC 🚀 — a TLR3 agonist booster that ignites interferon cascades, supercharging immune memory.
•CNPV 🎟️ — FDA’s Commissioner’s National Priority Voucher, reserved for pediatric cancers, compressing approval to 30–60 days.
And it’s not a concept. UCLA is running NCT06342908 right now, treating children with deadly H3 G34–mutant gliomas using AI-curated, peptide-pulsed dendritic cells under full GMP.
1️⃣ Where AI Enters the Fight
AI’s role isn’t vague here — it’s central.
•Data ingestion: IRIS consumes petabytes of tumor RNA-seq data from TCGA, CCDI’s pediatric cancer initiative, and GTEx.
•Error detection: Machine learning models identify splicing abnormalities — skipped exons, cryptic junctions, microexons — unseen in normal tissues.
•Ranking & prediction: Neural networks and probabilistic algorithms rank which peptides will bind MHC, remain stable, and be immunogenic.
•Validation: AI outputs are cross-checked against immunopeptidomics (mass spectrometry of tumor-displayed peptides) to prove they are real targets, not computer artifacts.
Without AI, this splicing chaos looks like noise. With AI, it’s a goldmine of targets. This is the only way to turn millions of aberrations into a short, validated antigen panel fast enough to matter for a sick child.
2️⃣ Why Pediatric Cancers Are the Perfect Fit
Traditional immunotherapies often fail in pediatrics because:
•Low mutation burden → not enough DNA mutations to create targets.
•Small patient numbers → difficult to run large randomized trials.
•Toxicity ceiling → children cannot tolerate the side effects of chemo, CAR-T, or systemic cytokines.
IRIS solves the first problem by unlocking splicing-derived targets, abundant in pediatric gliomas and sarcomas. DCVax solves the second by being safe, autologous, and already proven tolerable in hundreds of adults. Poly-ICLC addresses the third by providing an immune amplifier without systemic toxicity.
For children with survival measured in months, this is the architecture that finally fits.
3️⃣ From Algorithm to Immune Lesson
The IRIS → DCVax pipeline is beautifully direct:
1. Sequence the tumor → AI identifies splicing-derived peptides.
2. Curate & synthesize → GMP-grade peptides produced with sterility/purity checks.
3. Load onto DCs → dendritic cells derived from leukapheresis, matured, pulsed with IRIS peptides.
4. Infuse back → vaccine teaches T-cells to recognize those tumor-specific errors.
5. Boost with Poly-ICLC → expands response breadth and durability via TLR3-mediated interferon signaling.
This is what “AI cures cancer” looks like in practice — algorithms find the signals, dendritic cells deliver the lesson, boosters seal the memory.
4️⃣ Proof in Patients: UCLA’s Trial
At UCLA today (NCT06342908):
•Children and young adults with H3 G34–mutant gliomas are being treated.
•Dr. Robert Prins and Dr. Linda Liau lead — the same architects behind DCVax-L’s landmark glioblastoma trial.
•Tumors are sequenced, IRIS (or derivative pipelines) curate splicing-derived peptides.
•Vaccines are manufactured under full GMP in UCLA’s Gene & Cell Therapy Facility, using the same release standards as commercial ATMPs.
•Poly-ICLC is added as a booster.
This is the first active trial fusing AI antigen discovery with dendritic cell delivery in pediatric patients. It isn’t hype. It’s alive in children today.
The Voucher That Collapses Time
Normally, therapies for rare or pediatric cancers spend years grinding through the FDA review process. The new Commissioner’s National Priority Voucher (CNPV) program is designed to collapse that timeline.
•The FDA has announced this as a pilot program in 2025.
•In the first year, the agency plans to grant up to five vouchers total across all applicants.
•Each voucher allows the recipient therapy to be reviewed on an accelerated 30–60 day timeline, rather than the usual multi-year process.
•After the pilot, FDA has signaled that the number of vouchers may expand, but the initial run is tightly capped.
For NWBO, this matters enormously. DCVax is a platform, already validated and safe in adults. Adding IRIS peptides doesn’t create a brand-new product — it’s a spec update to the same chassis. That’s exactly the kind of refinement CNPV was built to accelerate.
If pediatric cancer programs qualify, NWBO’s submission could move in months, not years once filed under CNPV.
6️⃣ Eden: The Immune Forge
Eden isn’t just a machine. It’s the hardware kernel of the immune operating system.
•Patent-protected (EDITH, US 10,647,954 B1): covers perfusion geometry, anti-dead-zone flow, sterile transfer ports, programmed differentiation schedules.
•Closed system: eliminates contamination, standardizes DC output across sites.
•Plug-and-play: any antigen set (lysate, IRIS, or hybrid) can be dropped in without changing the licensed process.
Eden + SI 87 (UK law) means IRIS updates are controlled variations, not new licenses. The MHRA’s WHO-Listed Authority status means one UK approval can cascade into reliance markets globally.
That’s how AI findings become reproducible vaccines at scale.
7️⃣ The Human Face
Look back at Kennedy’s Oval Office photo: children at the desk, families behind them. These aren’t statistics. They are living proof of urgency.
For decades, pediatric glioma patients have been given months, not years. Radiation buys time at the cost of cognition. Chemo rarely works. CAR-T and mRNA can’t find targets.
Now AI can decode tumors for errors no child’s body has ever seen. DCVax can show those errors to the immune system. Poly-ICLC amplifies the response. And the voucher can collapse years into weeks.
This is the first time those families can look at a President’s words and know: the science is already here.
📜 Closing Thought
“AI will cure cancer” usually sounds like a politician’s flourish. But in pediatric oncology, the architecture already exists:
•AI (IRIS) finds the signals.
•DCVax delivers the immune lesson.
•Eden ensures reproducibility.
•Poly-ICLC strengthens memory.
•CNPV collapses time.
This isn’t just aspiration. It is a functioning system — alive in children right now, with regulatory rails ready to carry it worldwide.
👩⚕️ Plea to @SecKennedy
Families fighting pediatric brain cancer don’t have years to wait. IRIS + DCVax + Eden is already in children today. Please make sure these programs are prioritized for the first CNPV vouchers. Every month matters. Every child matters.
#NWBO $NWBO #DCVax #IRIS #Eden #Flaskworks #AI #CancerMoonshot #PediatricCancer #CNPV #Immunotherapy #RareDisease #Oncology #PrecisionMedicine
🔗 https://t.co/2Vnnttzluy
The MAHA Commission, under President Trump’s leadership, will ensure that every innovation and breakthrough goes to work for our children.
@BarackObama #Cancer don't hear #trump having goals initiatives except grift #gaslighting
@JoeBiden #CancerMoonShot continues as trump redirects funds from projects help all citizens have better quality of life to 🐂💩 convert #QATAR jet personal use via ILLEGAL emoluments
#VOTE🇺🇸💪🇺🇦👍🖖✅️
🔬 From the Lab to the White House 🇺🇸
Dr. Catharine Young’s journey began in apartheid-era South Africa and led her to shaping global #CancerPolicy at the highest level.
🚀 At the Biden #CancerMoonshot, she turned cutting-edge #science into real-world impact, fighting to make cancer care more equitable worldwide.
💡 Her mission? Make sure breakthroughs don’t just happen; they reach the people who need them most.
Read the full story of a #woman redefining what #leadership in science looks like:👇
https://t.co/cXShIHsiNO
@oncodaily
@thewhitehouse_u
@catgyoung
@shhovsepyan
#EndCancer #PrecisionMedicine #CancerResearch #GlobalCollaboration #HealthcareInnovation #Immunotherapy #CureForCancer #MedicalBreakthrough #CancerAwareness #Oncology #Cancer #Inspiration #Motivation #OncoDaily
$NWBO #NWBO #DCVax
“I’m NOT an Oncologist, but…”
I am a hospitalist. I’m also no biotech CEO. But I am a front-line witness to heartbreak, hope, and healing. I work - a lot. I realistically see over 5,000 patients a year (271 shifts last year and counting). I did my entire medical training during COVID from beginning to end. My grandfather died of esophageal cancer. My father has pancreatic cancer. So yes, I think I know a thing or two about loss.
But I also think I know a thing or two about hope when I see it, too. I can remember medical school stories from some of my older mentors talking to me about when beta-blockers were first invented, that even the Cardiologists didn’t know much about them. But every now and then, something comes along that changes the entire equation in the standard of care.
DCVax-L is no ordinary therapy. Phase III trial results demonstrate increased median overall survival, 5-year survival, and statistical significance. That’s not incremental, that’s meaningful. It means lives are extended. Time is granted. Wishes and prayers are answered. And it has virtually no side effect profile, if any. That means that the cost of time is not a price paid in functionality, or the trepidation of a treatment that might be just as bad, or worse, than the disease process itself.
Some analysts estimate with recent news and legislation, there is an 85-95% chance of approval by the MHRA. The FDA: while a more conservative estimate, there is a strong efficacy signal and no safety concerns, and approval odds sit at around 60-75%. Personally, I believe that approval is not a matter of if, but rather a matter of when. I believe that approval bodies know just how monumental this change is, and that they are doing their due diligence, carefully and cautiously, to ensure that it is done correctly. I believe in the Powers that be (pun intended). You don’t fight tooth and nail for every grueling, painstaking yard just to fumble in the end zone. Patience is key, and good things come to those who wait.
NWBO is no longer a fringe story, it’s an inflection point in immunotherapy for solid tumors. It isn’t just hype, it’s truly science with soul. And when it’s approved? It won’t just extend lives; it will redefine what’s possible for brain cancer patients who have been told there is nothing left to try. And that’s just the tip of the scalpel. Imagine what the future holds with further expansion. All solid tumors. Congestive heart failure. HIV. Autoimmune conditions. Alzheimers. The sky's the limit, and the only questions we might be asking in years to come is, “Why not?” and “Why didn’t we do this sooner?”
I understand others may not be as optimistic as I am. There isn’t just doubt, there’s confrontation. And I honestly do not understand why. If you’re not for it, that’s okay. Don’t buy it, don’t support it. But the vitriol? The hostility? The bizarre, obsessive anger for a potential cancer therapy? If you’re vehemently against it… Well, I can only surmise that it says something about your character and says a lot more about you than it does about the science.
“BuT tHe tRiAL uSeD eXteRnal CoNtrOL aRmS! ThE tRiAL diDn’T uSe a RanDOmiZeD cOnTRol gRouP!”
The FDA has issued clear guidance in orphan diseases like glioblastoma, and such methods are indeed acceptable when randomized trials are unethical. Randomization isn’t a religion, it’s a tool. When patients are dying and crossover is humane, you adapt. But hey, let’s not let ethics or patient lives get in the way of cynicism.
“ThE CoMPaNy’s BeEN aROunD foR 20 YeARs anD sTiLL nO FDA aPproVal! ThAt SaYS iT aLL!”
So has cancer. Time alone doesn’t invalidate progress. It often requires it. DCVax-L isn’t racing to market, it is literally paving a brand new road through immunotherapy for solid tumors. This path is likely significantly longer because it leads to somewhere truly revolutionary.
“ThE sTocK iS sO cHeAp! IF iT wAS sO gReAT thEN iT wOuLd bE wOrTH mOrE!”
Apple was once $2, Amazon was $0.07, and BitCoin was once for computer nerds trading it for video game swords and some poor sap that bought what is now the most expensive pizza known to man. Let’s not forget why (allegedly, but come on) the price is so low right now. NWBO isn’t a meme, it is unknown and misunderstood. Science moves slower than speculation, but when it catches up? Let’s just say that valuation adjusts with interest.
“If iT rEaLLy wOrKed, BiG pHaRma wOulD hAVe bOuGhT tHem bY nOw!”
And yet, the Wright Brothers flew without Boeing. True innovation of this magnitude does not wait for buyouts, it forces them (or makes them wish they had). Once the MHRA and other agencies move, Big Pharma will either knock or be left behind.
“THeY’Re jUsT tRYing to rAIsE mOrE MoNEy! THiS iS a PumP! YoU’Re jUsT biASeD bEcAuSe YoU’rE iNveStEd!”
Ah, yes. Because all late-stage biotech companies fund global immunotherapy development from couch cushions and spare change. If raising capital for a cure for cancer bothers you, I’m afraid that we differ on a lot more than investment strategy. I can’t fix a broken moral compass, even with expert guidance and a very clear sky. I sleep very comfortably and soundly at night knowing that my investment is in a cure for cancer, that it’s scientifically proven to be effective, and saves lives. Even if it should fail spectacularly and I lose everything, at least I fought for something worthwhile. Can you say the same?
Scoff at me if you want. Spam the comments if you feel like that helps you. Call out the credentials of a Physician saving lives daily in an Emergency Room for internet points in an echo chamber of a few sad and depraved nobodies. But when the approvals come, just remember; You weren’t just late to the table, you were mocking the fire while we were carrying the torch.
Doubt all you want. We’ll be busy saving lives.
We're close, and we all know it. Tick, tock...
Proud of the lasting legacy of the #CancerMoonshot and thrilled to be on @CBSNews today to talk about the importance of cancer research funding
https://t.co/sdGesd3SSz
Last Seen Hashtags on Sotwe
WWENXT
仙女棒
Seen from United States
守口如瓶
Seen from United States
goonette
Seen from United States
desi porn
Seen from Pakistan
ometv
Seen from United States
teen
istanbul gay
Seen from Turkey
momson()*************************
Seen from Brazil
omegle(**********)* filter:native_video
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
241.3M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
113M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.3M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.5M followers
KATY PERRY
@katyperry
89.1M followers
Taylor Swift
@taylorswift13
83M followers
Lady Gaga
@ladygaga
74.5M followers
Virat Kohli
@imvkohli
72M followers
Kim Kardashian
@kimkardashian
70.5M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
65M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62.2M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers